18  FDG-PET/CT for prognostic stratification of patients with multiple myeloma relapse after stem cell transplantation

Constantin Lapa; Katharina Lückerath; Uwe Malzahn; Samuel Samnick; Herrmann Einsele; Andreas K. Buck; Ken Herrmann; Stefan Knop

doi:10.18632/oncotarget.2290

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Clinical Research Papers:

¹⁸ FDG-PET/CT for prognostic stratification of patients with multiple myeloma relapse after stem cell transplantation

Constantin Lapa, Katharina Lückerath, Uwe Malzahn, Samuel Samnick, Herrmann Einsele, Andreas K. Buck, Ken Herrmann _ and Stefan Knop

PDF | HTML | How to cite

Oncotarget. 2014; 5:7381-7391. https://doi.org/10.18632/oncotarget.2290

Metrics: PDF 2795 views | HTML 3322 views | ?

Abstract

Constantin Lapa1*, Katharina Lückerath1*, Uwe Malzahn2,4, Samuel Samnick1, Herrmann Einsele3, Andreas K. Buck1 , Ken Herrmann1 and Stefan Knop3

1 Department of Nuclear Medicine,Medical Center, University of Würzburg, Würzburg

2 Institute of Clinical Epidemiology and Biometry, University of Würzburg, Würzburg

3 Department of Hematology and Oncology,Medical Center, University of Würzburg, Würzburg

4 Clinical Trial Center Würzburg, University Hospital Würzburg, Würzburg

* These authors contributed equally to this work

Correspondence:

Ken Herrmann, email:

Keywords: Multiple myeloma, molecular imaging, FDG-PET/CT

Received: June 30, 2014 Accepted: July 31, 2014 Published: July 31, 2014

Abstract

The aim of this study was to investigate the prognostic value of 18F-fluoro-deoxyglucose positron emission tomography–computed tomography (18F-FDG-PET/CT) in 37 patients with a history of multiple myeloma (MM) and suspected or confirmed recurrence after stem cell transplantation (SCT). All patients had been heavily pre-treated. Time to progression (TTP) and overall survival (OS) were correlated to a number of different PET-derived as well as clinical parameters. Impact on patient management was assessed.

Absence of FDG-avid MM foci was a positive prognostic factor for both TTP and OS (p<0.01). Presence of >10 focal lesions correlated with both TTP (p<0.01) and OS (p<0.05). Interestingly, presence of >10 lesions in the appendicular skeleton proved to have the strongest association with disease progression. Intensity of glucose uptake and presence of extramedullary disease were associated with shorter TTP (p=0.037 and p=0.049, respectively). Manifestations in soft tissue structures turned out to be a strong negative predictor for both, TTP and OS (p<0.01, respectively). PET resulted in a change of management in 30% of patients.

Our data underline the prognostic value of 18F-FDG-PET/CT in MM patients also in the setting of post-SCT relapse. PET/CT has a significant impact on patient management.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 2290

Publication Alerts

Clinical Research Papers:

18 FDG-PET/CT for prognostic stratification of patients with multiple myeloma relapse after stem cell transplantation

Abstract

¹⁸ FDG-PET/CT for prognostic stratification of patients with multiple myeloma relapse after stem cell transplantation